web analytics
9.4 C
Munich
Thursday, October 6, 2022

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) Coming Back After Major Short Attack While Biotech Reports Primary and Secondary Endpoints Met for DCVax®-L with Excellent Safety Profile

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) is moving northbound once again after a major short attack with at least 15 million shares sold short decimated the share price on Tuesday morning with NWBO hitting a low of $0.38 on the day before closing near the $1 mark. Tuesday the 10th of May should have been a great day, the Company reported positive results with data showing that patients treated with DCVax-L showed a clinically meaningful and statistically significant extension of survival, in both newly diagnosed and recurrent GBM. Primary endpoint was met (mOS in nGBM) with statistical significance, secondary endpoint met (mOS in rGBM) with statistical significance. The safety profile was excellent, with no autoimmune reactions and noteworthy long tails of survival. Dr. Linda Liau was supposed to shine in the spotlight however due to a covid sickness she could not attend and Dr. Paul Mulholland gave the presentation instead. While he did a fine job, the shorts used the confusion to capitalize and decimated the share price. Since than however, NWBO is coming back with power.  

https://www.youtube.com/watch?v=Z7oEWYwXcHA

While the results did not give the stock the short-term upside, they were looking for the presentation from Dr. Paul Mulholland proved that DCVax®-L is an effective treatment for the deadliest, most treatment resistant cancers. Glioblastoma multiforme (GBM) represents a potential market expected to reach $1.4 billion by 2025 and this is just the very beginning for DCVax®-L. These results alone should provide Linda Powers and her board ample bargaining power to sell NWBO’s proprietary vaccine to the highest bidder, which would readily be in the $10 to $20 billion market cap range.   

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) corporate headquarters are located at 4800 Montgomery Lane, Bethesda, Maryland, where NWBO leases and occupies an aggregate of approximately 7,097 square feet of office space. The lease covering this property is currently scheduled to expire in August 2024. The research and development operations are mainly based in Sawston, U.K., where the Company leases and occupies an aggregate of approximately 87,000 square feet of building. Microcapdaily has reported on NWBO numerous times, for more on the Sawston facility, Flaskworks, LLC, DCVax®-Direct, designed to treat inoperable solid tumors go here. 

NWBO lead product, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. We have completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). As previously reported, the data collection and confirmation process was conducted by the independent contract research organization (CRO) who managed the trial and by other independent service firms.  On October 5, 2020, the Company announced that Data Lock for the Phase III trial had been reached, and that a series of steps and processes would follow. These processes included data validation, analyses of the data by independent statisticians, preparations by the statisticians of summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, in preparation for publication in a scientific journal and public announcement.  This series of processes is under way.  It is anticipated that public announcement will follow these processes. 

https://twitter.com/FlemmingBruce/status/1524049008079130624

To Find out the inside Scoop on NWBO Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

NWBO

NWBO owns a valuable intellectual property portfolio; as of December 31, 2021, the Company had 204 issued patents and 59 pending patent applications worldwide, grouped into 11 patent families. Of these, 200 issued patents and 47 pending patent applications directly relate to the Company’s DCVax products. During 2021, seven new patents were issued to the Company as part of its worldwide patent portfolio. The newly issued patents cover methods for manufacturing dendritic cells related to its DCVax products, as well as encompassing certain methods of use and compositions that may be potential future markets for related DCVax products. Additionally, with the acquisition of Flaskworks, Northwest gained ownership of a portfolio of patents and patent applications which include those held by Flaskworks as well as patents and patent applications exclusively licensed by Flaskworks from Northeastern University. The portfolio includes a total of thirteen patent families, with issued patents and pending applications worldwide. Collectively these patents and patent applications cover key aspects of the design and function of automated cell culture systems.   

In addition to its patent portfolio, Northwest has obtained Orphan Drug designation for its lead product, DCVax-L for glioma brain cancers. Such designation brings with it a variety of benefits, including potential market exclusivity for seven years in the U.S. and ten years in Europe if its product is the first of its type to reach the market. 

For More on NWBO Subscribe Right Now!

NWBO has some exciting days ahead as the stock price was artificially lowered while the Company reported primary and secondary endpoints were met with an excellent safety profile. Dr. Linda Liau was supposed to shine in the spotlight however due to a covid sickness she could not attend and Dr. Paul Mulholland gave the presentation instead. While he did a fine job, the shorts used the confusion to capitalize and decimated the share price.  The data shows that patients treated with DCVax-L showed a clinically meaningful and statistically significant extension of survival, in both newly diagnosed and recurrent GBM. Primary endpoint was met (mOS in nGBM) with statistical significance, secondary endpoint met (mOS in rGBM) with statistical significance. The safety profile was excellent, with no autoimmune reactions and noteworthy long tails of survival. NWBO is looking to move back over $2 after the stock was attacked by an aggressive short selling scheme that sold at least 15 million shares short.  Glioblastoma multiforme (GBM) represents a potential market expected to reach $1.4 billion by 2025 and this is just the very beginning for DCVax®-L. These results alone should provide Linda Powers and her board ample bargaining power to sell NWBO’s proprietary vaccine to the highest bidder, which would readily be in the $10 to $20 billion market cap range. The presentation can be seen here: https://events.nyas.org/event/28ca5e39-51a7-4e73-be3d-78089c92d596/summary   Microcapdaily gave the heads up on NWBO on February 3, 2020 when the stock was $0.18 per share in our article: The Exciting Story of Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) We will be updating on NWBO as more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in NWBO either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.